AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL
DeviceMultifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
Other names: SN6AD1
NCT Number: NCT01290068
The purpose of this study is to assess and compare visual outcomes of the AcrySof® IQ ReSTOR® +3.0 D intraocular lens (IOL) to a commercially available monofocal IOL in cataract patients.
Looking for future studies?
Notify Me21 year and older
All sexes
Interventional
Not applicable
This study included subjects with bilateral age-related cataracts and either no preoperative corneal astigmatism, or preoperative regular corneal astigmatism confirmed by autokeratometry of ≤2.5 D.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
Other names: SN6AD1
Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
Other names: SND1T2, SND1T3, SND1T4, SND1T5
Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
Time frame: Month 6 after second eye implantation
Distance VA and near VA were measured binocularly (both eyes together) without visual correction using ETDRS (Early Treatment of Diabetic Retinopathy Study) charts positioned at a consistent, manufactured distance. VA was measured in logMAR (logarithm of the minimum angle of resolution), with a lower logMAR value indicating better visual acuity. A responder was defined as a participant who achieved bilateral uncorrected distance visual acuity and bilateral uncorrected near visual acuity of ≤0.1 LogMAR at the Month 6 visit.
Time frame: Month 6 after second eye implantation
Spectacle independence at all distances; ie, where type of spectacles used/prescribed equaled 'No spectacles', was evaluated. If for the 6-month visit, spectacle type information was missing for the spectacle independence endpoint, but the subject attended this 6-month visit, subject was assumed to be spectacle independent.
Time frame: Month 6 after second eye implantation
Vision-related quality of life dimensions were evaluated using the National Eye Institute Refractive Error Quality of Life instrument (NEI-RQL 42), a self-administered questionnaire. Each dimension was scored between 0 to 100, with a higher score indicating a better vision-related Quality of Life. 5 of the dimensions were prespecified as primary.
Time frame: Month 6 after second eye implantation
Total spectacle cost includes the frame, lens, and any reimbursement from national health systems or private insurance. Costs collected in pounds sterling were converted to euros.
Alcon Research
Industry
Visual Outcomes After Bilateral Surgical Cataract Phacoemulsification: AcrySof® ReSTOR IOL Implantation Compared to Monofocal IOL Implantation
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07086118
Cataract, Dexamethasone
Alexandria, Egypt
View Trial DetailsNCT06264830
Cataract, Eye Diseases
Taipei, Taiwan
View Trial DetailsNCT07767643
Anxiety, Anxiety Disorders
Yatağan, Muğla, Turkey (Türkiye)
View Trial DetailsNCT06555770
Anxiety Disorders, Cataract
Samsun, Turkey (Türkiye)
View Trial Details